Quantcast

CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Research paper by Adolfo Quiñones AQ Lombraña, Nasi N Li, Virginia V Del Solar, G G Ekin Atilla-Gokcumen, Javier G JG Blanco

Indexed on: 01 Jun '18Published on: 01 Jun '18Published in: Biopharmaceutics & Drug Disposition



Abstract

Loxoprofen is an anti-inflammatory drug that requires bioactivation into the trans-OH metabolite to exert pharmacological activity. Evidence suggests that carbonyl reductase 1 (CBR1) is important during the bioactivation of loxoprofen. Here, we examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples. The synthesis ratios of trans-OH loxoprofen/cis-OH loxoprofen were 33% higher in liver cytosols from donors homozygous for the CBR1 rs9024 G allele in comparison to the ratios in samples from donors with heterozygous GA genotypes. Complementary studies examined the impact of CBR1 rs9024 on the bioactivation of loxoprofen in lymphoblastoid cell lines. CBR1 rs9024 genotype status impacts the synthesis of the bioactive trans-OH metabolite of loxoprofen in human liver. This article is protected by copyright. All rights reserved.